Affiliation:
1. From the Departments of Surgery and Circulatory Physiology (H.R.L.), College of Physicians and Surgeons, Columbia University, New York, NY; and the Cleveland Clinic Foundation (R.L.V., P.M.M.), Cleveland, Ohio.
Abstract
Background
Although use of long-term implantable left ventricular assist devices (LVAD) is becoming more popular, further reduction of the mortality rate accompanying device insertion through improved patient selection would make this alternative even more appealing. We sought to develop a scoring system that was based on criteria obtainable at the time of evaluation and predictive of successful early outcome and simple to apply.
Methods and Results
Patients (n=56) undergoing LVAD insertion between 1990 and 1994 were screened for easily obtainable preoperative risk factors. To test the association between survival and each risk factor, a χ
2
analysis was performed, and relative risks were estimated. Oliguria, ventilator dependence, elevated central venous pressure, elevated prothrombin time, and reoperation status had low probability values and high estimated relative risks. On the basis of these relations, a risk factor–selection scale (RFSS) (range, 0 to 10) was developed by computing appropriate weights for each risk factor. The distribution of patients for each scale score reveal that with RFSS ≥5, most device recipients will die (
P
<.001). The average RFSS (±SD) of survivors (n=42) was 2.45±1.73 compared with 5.43±2.85 in nonsurvivors (n=14) (
P
<.0001). Univariate logistical regression was also significant (score statistic, 16.2;
df
=1;
P
=.001).
Conclusions
The RFSS is simple, easy to apply, and statistically valid. Physicians could use the scale as a starting point in discussing the suitability for LVAD implantation in a specific patient and as a basis for comparing patient outcomes.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Subject
Physiology (medical),Cardiology and Cardiovascular Medicine
Reference13 articles.
1. Medical Devices Diagnostics and Instrumentation Reports . Chevy Chase Md: F-D-C Reports Inc; October 10 1994.
2. Multicenter clinical evaluation of the HeartMate 1000 IP left ventricular assist device
3. Clinical experience with the Novacor ventricular assist system
4. Goldstein DJ Seldomridge JA Chen JM Catanese KA DeRosa CM Weinberg AD Smith CR Rose EA Levin HR Oz MC. Use of aprotinin in LVAD recipients reduces blood loss and associated right heart failure. Ann Thorac Surg .
Cited by
144 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献